Sepsis Clinical Trial
— SNV-SepsisOfficial title:
Randomized Pilot Study Evaluating the Effectiveness of Non-invasive Vagus Nerve Stimulation as an Adjuvant Treatment in Patients With Sepsis in Intensive Care.
Sepsis is one of the leading causes of death in intensive care. About 50% of patients with septic shock die after 1 year; and 50% of survivors suffer from cognitive decline. The pathophysiological mechanisms of serious complications of sepsis are now well known. In fact, the systemic inflammation related to sepsis amplifies the release of pro-inflammatory cytokines and neurotoxic mediators, hence an increase in deleterious phenomena such as oxidative stress, mitochondrial dysfunction, endothelial activation, disruption of the blood-brain barrier, neuroinflammation (astrocytic and microglial activation) leading to multi-organ failure which compromises the patient's vital and functional prognosis. Although there has been progress in the understanding of its pathophysiology, the management of sepsis and septic shock in intensive care relies mainly on anti-infective treatments and the restoration of cardiovascular and respiratory functions. There is virtually no adjuvant therapy for the management of sepsis, apart from a few hormonal therapies such as insulin to maintain blood glucose levels below 180 mg / dL and low doses of corticosteroids and vasopressin. There is therefore a pressing need to develop innovative treatments targeting inflammatory and immunological processes in order to reduce the complications of sepsis and improve patient prognosis. Some recent work has shown that electrical vagus nerve stimulation (SNV), a technique used for the treatment of drug-resistant epilepsy, can modulate inflammatory and immune responses and control inflammation syndrome in animal models of sepsis, arthritis and rheumatism in humans. In this pilot study the investigators plan to evaluate the efficacy of transcutaneous (non-invasive) SNV as an adjuvant treatment in patients with sepsis in intensive care.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | March 29, 2023 |
Est. primary completion date | March 29, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age> 18 years old - Adult man or woman, hospitalized in intensive care, presenting with sepsis for at least 24 hours according to the diagnostic criteria (Singer et al., 2016). Exclusion Criteria: - Patient under guardianship, - Patient in a severe state of agitation. - Patient in a state of brain death or active limitation of treatment. - Multiple trauma patient, with multiple fractures of the skull. - Refusal to participate in the study or to sign the informed consent by the patient or his loved one, - Pregnant or breastfeeding woman, - No affiliation to a social security scheme. |
Country | Name | City | State |
---|---|---|---|
France | Raymond Poincaré Hospital | Garches |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality | Overall death | at day 90 | |
Secondary | Cumulative incidence of delirium and its duration | up to day 90 | ||
Secondary | Cumulative incidence of mechanical ventilation and its duration | up to day 90 | ||
Secondary | Proportion of patients having been the subject of a decision to limit or withdraw care | at day 90 | ||
Secondary | Duration of use of vasopressors | at day 90 | ||
Secondary | Number of days alive with a SOFA score <6 | at day 90 | ||
Secondary | Length of stay in intensive care and hospitalization in all patients and in survivors | at day 90 | ||
Secondary | Measurements of changes in C-reactive protein (CRP) | at inclusion | ||
Secondary | Measurements of changes in C-reactive protein (CRP) | at day 7 | ||
Secondary | Measurements of changes in C-reactive protein (CRP) | at day 14 | ||
Secondary | Measurements of changes in C-reactive protein (CRP) | at day 21 | ||
Secondary | Measurements of changes in C-reactive protein (CRP) | at day 28 | ||
Secondary | Measurements of changes in C-reactive protein (CRP) | at day 90 | ||
Secondary | Measurements of changes in fibrinogen level | at inclusion | ||
Secondary | Measurements of changes in fibrinogen level | at day 7 | ||
Secondary | Measurements of changes in fibrinogen level | at day 14 | ||
Secondary | Measurements of changes in fibrinogen level | at day 21 | ||
Secondary | Measurements of changes in fibrinogen level | at day 28 | ||
Secondary | Measurements of changes in fibrinogen level | at day 90 | ||
Secondary | Measurements of changes in interleukin-6 (IL-6) | at inclusion | ||
Secondary | Measurements of changes in interleukin-6 (IL-6) | at day 7 | ||
Secondary | Measurements of changes in interleukin-6 (IL-6) | at day 14 | ||
Secondary | Measurements of changes in interleukin-6 (IL-6) | at day 21 | ||
Secondary | Measurements of changes in interleukin-6 (IL-6) | at day 28 | ||
Secondary | Measurements of changes in interleukin-6 (IL-6) | at day 90 | ||
Secondary | Measurements of changes in interleukin-1ß (IL-1ß) | at inclusion | ||
Secondary | Measurements of changes in interleukin-1ß (IL-1ß) | at day 7 | ||
Secondary | Measurements of changes in interleukin-1ß (IL-1ß) | at day 14 | ||
Secondary | Measurements of changes in interleukin-1ß (IL-1ß) | at day 21 | ||
Secondary | Measurements of changes in interleukin-1ß (IL-1ß) | at day 28 | ||
Secondary | Measurements of changes in interleukin-1ß (IL-1ß) | at day 90 | ||
Secondary | Measurements of changes in tumor necrosis factor a (TNF-a) | at inclusion | ||
Secondary | Measurements of changes in tumor necrosis factor a (TNF-a) | at day 7 | ||
Secondary | Measurements of changes in tumor necrosis factor a (TNF-a) | at day 14 | ||
Secondary | Measurements of changes in tumor necrosis factor a (TNF-a) | at day 21 | ||
Secondary | Measurements of changes in tumor necrosis factor a (TNF-a) | at day 28 | ||
Secondary | Measurements of changes in tumor necrosis factor a (TNF-a) | at day 90 | ||
Secondary | Measurements of changes in the calcium binding protein B S100B (S100B) | at inclusion | ||
Secondary | Measurements of changes in the calcium binding protein B S100B (S100B) | at day 7 | ||
Secondary | Measurements of changes in the calcium binding protein B S100B (S100B) | at day 14 | ||
Secondary | Measurements of changes in the calcium binding protein B S100B (S100B) | at day 21 | ||
Secondary | Measurements of changes in the calcium binding protein B S100B (S100B) | at day 28 | ||
Secondary | Measurements of changes in the calcium binding protein B S100B (S100B) | at day 90 | ||
Secondary | Measurements of changes in the arterial lactate level | at inclusion | ||
Secondary | Measurements of changes in the arterial lactate level | at day 7 | ||
Secondary | Measurements of changes in the arterial lactate level | at day 14 | ||
Secondary | Measurements of changes in the arterial lactate level | at day 21 | ||
Secondary | Measurements of changes in the arterial lactate level | at day 28 | ||
Secondary | Measurements of changes in the arterial lactate level | at day 90 | ||
Secondary | Characteristics of the EEG | at inclusion | ||
Secondary | Characteristics of the EEG | at day 7 | ||
Secondary | Mortality rate | Overall death | at day 28 | |
Secondary | Neurological fate of patients | Neurological fate of patients will evaluated using Glasgow Outcome Scale - GOS | at day 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |